MDxHealth (MDXH) to Release Earnings on Wednesday

MDxHealth (NASDAQ:MDXH) is expected to issue its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect MDxHealth to post earnings of ($0.1447) per share and revenue of $30.8920 million for the quarter. Parties can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:30 PM ET.

MDxHealth (NASDAQ:MDXH) last posted its earnings results on Friday, February 27th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.04). The business had revenue of $29.55 million during the quarter, compared to analyst estimates of $26.05 million. MDxHealth had a negative net margin of 31.07% and a negative return on equity of 1,078.01%. On average, analysts expect MDxHealth to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MDxHealth Price Performance

NASDAQ MDXH opened at $2.00 on Monday. MDxHealth has a one year low of $1.70 and a one year high of $5.33. The firm has a market cap of $99 million, a P/E ratio of -2.99 and a beta of 1.60. The stock’s 50-day moving average is $2.64 and its 200-day moving average is $3.33.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of MDxHealth in a research note on Friday, March 27th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, MDxHealth presently has a consensus rating of “Moderate Buy” and an average target price of $7.75.

Institutional Trading of MDxHealth

A number of institutional investors have recently modified their holdings of MDXH. Intesa Sanpaolo Wealth Management bought a new position in shares of MDxHealth during the fourth quarter worth about $36,000. Lido Advisors LLC acquired a new position in MDxHealth during the 3rd quarter worth approximately $48,000. Citadel Advisors LLC grew its stake in shares of MDxHealth by 30.6% during the 3rd quarter. Citadel Advisors LLC now owns 48,938 shares of the company’s stock worth $228,000 after acquiring an additional 11,456 shares in the last quarter. Jefferies Financial Group Inc. bought a new position in shares of MDxHealth during the 3rd quarter worth approximately $53,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of MDxHealth in the fourth quarter valued at approximately $51,000.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.